![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Medgenics(Regs) | LSE:MEDG | London | Ordinary Share | COM SHS USD0.0001 (REGS) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 302.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMMEDG TIDMMEDU
RNS Number : 0662I
Medgenics Inc
08 June 2011
Medgenics, Inc.
(the "Company")
Issue of Equity and Director/PDMR Shareholding
8 June 2011
Medgenics, Inc. (NYSE Amex: MDGN and MDGN.W and London Stock Exchange - AIM: MEDG and MEDU), the company that has developed a novel technology for the manufacture and delivery of therapeutic proteins continuously in patients using their own tissue, announces that on May 12, 2011 the Company issued a total of 22,945 new common shares of par value U.S. $0.0001 each in the Company ("Common Shares") and on May 27, 2011 the Company issued 18,269 new Common Shares as a result of exercises of options over and above the remaining capacity available under the Company's existing Block Admission- which exhausted remaining capacity in the six months to June 4, 2011 as announced on June 8, 2011.
This issue of Common Shares includes the issue of 18,269 Common Shares to Gary Brukardt, a director of the Company, following the exercise of 60,507 warrants (with an exercise price of U.S. $2.49 per Common Share) to subscribe for new Common Shares using the cashless exercise mechanism on 27 May 2011. As a result of this exercise of warrants, Gary Brukardt is now interested in a total of 49,880 Common Shares. This holding represents approximately 0.5 per cent of the Company's issued share capital.
In addition to his interest in the Company's common share capital, Mr. Brukardt is interested in the following options and warrants to subscribe for Common Shares:
% of % of Issued Issued Common Share Expiry Exercise Total Share Shares Capital Instrument Number Date Price Interests Capital ----------- ------ ------- ---------- -------- ---------- -------- --------- ------- Gary Brukardt (Director) 49,880 ----------- ------ ------- ---------- -------- ---------- -------- --------- ------- Options 45,701 18/09/2011 $2.49 ----------- ------ ------- ---------- -------- ---------- -------- --------- ------- Options 26,705 14/11/2012 $7.35 ----------- ------ ------- ---------- -------- ---------- -------- --------- ------- Options 28,571 14/09/2020 $8.19 ----------- ------ ------- ---------- -------- ---------- -------- --------- ------- Options 12,857 12/01/2021 $6.55 ----------- ------ ------- ---------- -------- ---------- -------- --------- ------- Total 49,880 0.5% 113,834 163,714 1.7% ----------- ------ ------- ---------- -------- ---------- -------- --------- -------
Application will been made for the new Common Shares, which rank pari passu with the Company's existing issued share capital, to be admitted to trading on AIM and it is expected that the admission will occur on June 15, 2011.
Following the issue and allotment of the new Common Shares referred to herein and the 170,501 issued under the Company's existing Block Admission, the Company will have a total of 9,631,198 Common Shares in issue and the percentage of shares not in public hands will be 32.9%.
The Company has also made an application for a block admission, in accordance with the AIM Rules, for 1,926,239 Common Shares (in relation to the Company's outstanding warrants and options under its share incentive plans) which represents approximately 20% of the Company's currently issued share capital. It is expected that this block admission will be effective from June 15, 2011.
For further information, contact:
Medgenics, Inc. Phone: +972 4 902 8900 Dr. Andrew L. Pearlman Religare Capital Markets (Nominated Phone: +44 20 7444 0800 Adviser) James Pinner Derek Crowhurst SVS Securities plc (Joint Broker) Phone: +44 20 7638 5600 Ian Callaway Nomura Code Securities PLC (Joint Phone: +44 20 7776 1219 Broker) Jon Senior De Facto Financial Phone: +44 207 556 1064 Mike Wort Anna Dunphy Lippert/Heilshorn & Associates, Inc. Phone: +1 212-838-3777 (Investment Relations - US) Anne Marie Fields
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSEAPKPEFPFEEF
1 Year Medgenics(Regs) Chart |
1 Month Medgenics(Regs) Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions